var data={"title":"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/contributors\" class=\"contributor contributor_credentials\">L Darryl Quarles, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/contributors\" class=\"contributor contributor_credentials\">Michael Berkoben, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/contributors\" class=\"contributor contributor_credentials\">Stanley Goldfarb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/contributors\" class=\"contributor contributor_credentials\">Alice M Sheridan, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 01, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic kidney disease mineral and bone disorder (CKD-MBD) is characterized by biochemical abnormalities (calcium, phosphate, parathyroid hormone [PTH], and vitamin D); abnormalities in bone turnover, mineralization, volume linear growth, or strength; and by extraskeletal calcification.</p><p>Secondary hyperparathyroidism encompasses the biochemical abnormalities of CKD-MBD (ie, calcium, phosphate, PTH, vitamin D).</p><p>This topic reviews our approach to the treatment of secondary hyperparathyroidism in CKD patients who are not on dialysis.</p><p>The management of secondary hyperparathyroidism in dialysis patients, the treatment of hyperphosphatemia, and indications for parathyroidectomy in patients with end-stage renal disease (ESRD) are presented separately. (See <a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-dialysis-patients\" class=\"medical medical_review\">&quot;Management of secondary hyperparathyroidism in dialysis patients&quot;</a> and <a href=\"topic.htm?path=management-of-hyperphosphatemia-in-chronic-kidney-disease\" class=\"medical medical_review\">&quot;Management of hyperphosphatemia in chronic kidney disease&quot;</a> and <a href=\"topic.htm?path=refractory-hyperparathyroidism-and-indications-for-parathyroidectomy-in-dialysis-patients\" class=\"medical medical_review\">&quot;Refractory hyperparathyroidism and indications for parathyroidectomy in dialysis patients&quot;</a>.)</p><p>The pathogenesis and clinical features of CKD-MBD are discussed separately. (See <a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd#H4\" class=\"medical medical_review\">&quot;Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)&quot;, section on 'Overview'</a>.)</p><p class=\"headingAnchor\" id=\"H1301799786\"><span class=\"h1\">RATIONALE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sustained elevated parathyroid hormone (PTH) levels can cause high-turnover bone disease (osteitis fibrosa cystica), fracture, hypercalcemia and hyperphosphatemia, and calciphylaxis. (See <a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd#H4\" class=\"medical medical_review\">&quot;Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)&quot;, section on 'Overview'</a>.)</p><p class=\"headingAnchor\" id=\"H2395990131\"><span class=\"h1\">ASSESSMENT AND MONITORING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We monitor all patients with estimated glomerular filtration rate (eGFR) &lt;60 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup> for the development of secondary hyperparathyroidism. Secondary hyperparathyroidism is very common in CKD and is present in the majority of patients with eGFR &lt;60 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup> [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/1\" class=\"abstract_t\">1</a>]. We measure serum levels of calcium, phosphate, parathyroid hormone (PTH), and vitamin D (25(OH)D or calcidiol) [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/2\" class=\"abstract_t\">2</a>].</p><p>We do not routinely perform bone biopsies, although they are the gold standard for the diagnosis of bone disease in CKD patients. There are specific circumstances in which a bone biopsy may be indicated. (See <a href=\"topic.htm?path=bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy\" class=\"medical medical_review\">&quot;Bone biopsy and the diagnosis of renal osteodystrophy&quot;</a>.)</p><p>We do not routinely screen for vascular calcification with imaging tests. Although vascular calcification is part of the spectrum of chronic kidney disease mineral and bone disorder (CKD-MBD) and may identify patients at increased cardiovascular mortality, documenting whether or not it is present does not change our approach to patients; we assume all patients are at risk for or have some degree of vascular calcification.</p><p>The optimal frequency of monitoring is unknown. Our approach depends on the eGFR [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H4215055417\"><span class=\"h2\">eGFR 30 to 59 mL/min/1.73 m2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with estimated glomerular filtration rate (eGFR) 30 to 59 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>, we measure serum calcium and phosphate every 6 to 12 months. We measure PTH every 12 months. These levels may be assessed more frequently in patients who are being treated for abnormal values. As an example, patients who are treated for hyperphosphatemia may be assessed every three months. However, it is unusual to observe hyperphosphatemia until the eGFR decreases to &lt;30 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>.</p><p>We measure vitamin D concentrations at least yearly. Patients who have increased PTH or who are being treated for 25(OH)D deficiency are tested every six months.</p><p class=\"headingAnchor\" id=\"H632673499\"><span class=\"h2\">eGFR 15 to 29 mL/min/1.73 m2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with estimated glomerular filtration rate (eGFR) 15 to 29 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>, we measure serum calcium and phosphate every three to six months. We measure PTH every 6 to 12 months. These levels may be assessed more frequently in patients who are being treated for abnormal values.</p><p>We measure vitamin D concentrations at least yearly. Patients who have increased PTH or who are being treated for 25(OH)D deficiency are tested every six months.</p><p class=\"headingAnchor\" id=\"H533307997\"><span class=\"h2\">eGFR &lt;15 mL/min/1.73 m2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with estimated glomerular filtration rate (eGFR) &lt;15 to 29 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>, we measure serum calcium and phosphate every one to three months. We measure PTH a minimum of every three to six months. The frequency of testing depends on whether the patient is being treated or not.</p><p>We measure vitamin D concentrations at least yearly. Patients who have increased PTH or who are being treated for 25(OH)D deficiency are tested every six months.</p><p class=\"headingAnchor\" id=\"H1752618100\"><span class=\"h1\">INITIAL TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serial assessment of phosphate, calcium, vitamin D, and parathyroid hormone (PTH) levels provides indications for treatment. Our approach is consistent with the 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H1051197753\"><span class=\"h2\">Treat hyperphosphatemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We generally treat patients who have a serum phosphate that is persistently above normal. (See <a href=\"topic.htm?path=management-of-hyperphosphatemia-in-chronic-kidney-disease#H89993305\" class=\"medical medical_review\">&quot;Management of hyperphosphatemia in chronic kidney disease&quot;, section on 'Nondialysis chronic kidney disease patients'</a>.)</p><p>Treatment primarily consists of dietary phosphate restriction and the use of noncalcium-containing phosphate binders to maintain normal or near-normal serum phosphate values. (See <a href=\"topic.htm?path=management-of-hyperphosphatemia-in-chronic-kidney-disease#H89993305\" class=\"medical medical_review\">&quot;Management of hyperphosphatemia in chronic kidney disease&quot;, section on 'Nondialysis chronic kidney disease patients'</a>.)</p><p class=\"headingAnchor\" id=\"H3299247461\"><span class=\"h2\">Hypocalcemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our approach to hypocalcemia is individualized and depends on severity and presence of symptoms [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/2\" class=\"abstract_t\">2</a>].</p><p>We do not specifically treat asymptomatic and mild hypocalcemia (ie, &gt;7.5 <span class=\"nowrap\">mg/dL</span> in the setting of normal albumin) with either calcium or vitamin D derivatives (such as <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> or synthetic vitamin D analogs). There is a significant risk of hypercalcemia with these agents. However, we do use these agents to treat severe and progressive hyperparathyroidism. (See <a href=\"#H2773888503\" class=\"local\">'Treat persistent and progressive hyperparathyroidism'</a> below.)</p><p>Mild hypocalcemia may be addressed in part by the treatment of vitamin deficiency. Nutritional vitamin D deficiency contributes to hypocalcemia. (See <a href=\"#H2953807510\" class=\"local\">'Treat vitamin D deficiency'</a> below.)</p><p>In addition, the treatment of hyperphosphatemia may also help to treat mild hypocalcemia. (See <a href=\"#H1051197753\" class=\"local\">'Treat hyperphosphatemia'</a> above and <a href=\"topic.htm?path=management-of-hyperphosphatemia-in-chronic-kidney-disease#H89993305\" class=\"medical medical_review\">&quot;Management of hyperphosphatemia in chronic kidney disease&quot;, section on 'Nondialysis chronic kidney disease patients'</a>.) &#160;</p><p>Hypocalcemia has been associated with higher mortality in observational studies [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/3\" class=\"abstract_t\">3</a>] and contributes to hyperparathyroidism [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/2\" class=\"abstract_t\">2</a>]. However, there is concern that the administration of oral calcium (ie, calcium-containing phosphate binders) and vitamin D analogs will cause hypercalcemia, which may result in vascular calcification. (See <a href=\"#H2773888503\" class=\"local\">'Treat persistent and progressive hyperparathyroidism'</a> below.)</p><p class=\"headingAnchor\" id=\"H2953807510\"><span class=\"h2\">Treat vitamin D deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We treat vitamin D deficiency according to guidelines for the general population. Among CKD patients, vitamin D (ie, cholecalciferol or ergocalciferol) should not be given in the setting of elevated serum phosphate levels.</p><p>Vitamin D should also not be given if the corrected serum total calcium concentration is at or above the upper limit of normal (ie, &ge;9.5 <span class=\"nowrap\">mg/dL</span> [&ge;2.37 <span class=\"nowrap\">mmol/L])</span> [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment\" class=\"medical medical_review\">&quot;Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment&quot;</a>.)</p><p>Vitamin D deficiency is a common finding in CKD patients. Vitamin D deficiency is associated with elevated PTH levels and may worsen hypocalcemia. </p><p>The efficacy of vitamin D supplementation on mineral metabolism <span class=\"nowrap\">and/or</span> other outcomes has not been established in CKD patients [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/5\" class=\"abstract_t\">5</a>]. A few studies have found that such therapy normalizes serum 25(OH)D levels and modestly decreases PTH levels [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/6-8\" class=\"abstract_t\">6-8</a>]. A meta-analysis that included nine observational studies comprising 286 nondialysis patients reported improvements in vitamin D and PTH levels associated with vitamin D supplementation [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/9\" class=\"abstract_t\">9</a>]. A low incidence of hypercalcemia and hyperphosphatemia was reported in this study.</p><p class=\"headingAnchor\" id=\"H2773888503\"><span class=\"h2\">Treat persistent and progressive hyperparathyroidism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We treat all patients with persistently elevated or progressively rising PTH for modifiable risk factors including hyperphosphatemia, high phosphate intake, and vitamin D deficiency.</p><p>Treatment should not be initiated based on a single elevated value, as modest or transient elevations of PTH may reflect an adaptive response to declining kidney function (ie, related to phosphaturic effects and bone resistance to PTH).</p><p>If the PTH remains significantly and progressively elevated despite treating modifiable risk factors, we treat with the vitamin D derivative, <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a>. The threshold for treating persistently elevated PTH with calcitriol or synthetic vitamin D analogs is not well defined and varies among clinicians. We treat most patients who have PTH &gt;2.3 to 3 times the upper limit for the assay (ie, 150 to 200 <span class=\"nowrap\">pg/mL</span> if upper limit for the assay is 65 <span class=\"nowrap\">pg/mL)</span>.</p><p>A preferred dose is 0.25 mcg three times weekly. We adjust the dose to maintain PTH &lt;150 <span class=\"nowrap\">pg/mL</span>. We do not use <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> if the serum phosphate is above normal range or if the corrected serum total calcium concentration is &ge;9.5 <span class=\"nowrap\">mg/dL</span> (&ge;2.37 <span class=\"nowrap\">mmol/L)</span>.</p><p><a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">Calcitriol</a> and synthetic vitamin D derivatives have been shown to reduce or stabilize PTH and improve bone histology [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/10-14\" class=\"abstract_t\">10-14</a>]. However, these agents have not been shown to improve clinically important outcomes and have been associated with an increased risk of hypercalcemia [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/15,16\" class=\"abstract_t\">15,16</a>]. In one randomized trial, the synthetic vitamin D derivative, <a href=\"topic.htm?path=paricalcitol-drug-information\" class=\"drug drug_general\">paricalcitol</a>, had no effect on left ventricular mass index or diastolic function but increased the risk of hypercalcemia, defined as two consecutive measurements &gt;10.5 <span class=\"nowrap\">mg/dL</span> (23 percent versus 1 percent in placebo) [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The comparative effects of <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> or the different synthetic vitamin D derivatives have not been established in nondialysis CKD patients. As a result, any one of the available oral agents (calcitriol, <a href=\"topic.htm?path=alfacalcidol-united-states-not-available-drug-information\" class=\"drug drug_general\">alfacalcidol</a>, <a href=\"topic.htm?path=doxercalciferol-drug-information\" class=\"drug drug_general\">doxercalciferol</a>, or <a href=\"topic.htm?path=paricalcitol-drug-information\" class=\"drug drug_general\">paricalcitol</a>) may be administered [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/10,17\" class=\"abstract_t\">10,17</a>].</p><p>We do not use vitamin D supplements to suppress PTH in the absence of documented vitamin D deficiency [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/4\" class=\"abstract_t\">4</a>].</p><p>We do not use the calcimimetic, <a href=\"topic.htm?path=cinacalcet-drug-information\" class=\"drug drug_general\">cinacalcet</a>, to suppress PTH among nondialysis CKD patients. Although cinacalcet decreases PTH levels, it is associated with hypocalcemia and increased urinary calcium excretion [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/18,19\" class=\"abstract_t\">18,19</a>]. Because of the risk of hypocalcemia, laboratory values require close monitoring (weekly after starting therapy or change in dose), which may be difficult in the outpatient setting.</p><p>The KDIGO 2017 guideline does not provide recommendations on the use of <a href=\"topic.htm?path=cinacalcet-drug-information\" class=\"drug drug_general\">cinacalcet</a> [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/2\" class=\"abstract_t\">2</a>]. Prior KDIGO guidelines suggested that cinacalcet not be used given the paucity of data concerning efficacy and safety in predialysis patients with CKD [<a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To monitor for secondary hyperparathyroidism among patients with estimated glomerular filtration rate (eGFR) &lt;60 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>, we measure serum levels of calcium, phosphate, parathyroid hormone (PTH), and vitamin D (25(OH)D or calcidiol). Our approach depends on the eGFR and is defined above. (See <a href=\"#H2395990131\" class=\"local\">'Assessment and monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with persistently elevated or progressively rising PTH should be evaluated for modifiable risk factors such as hyperphosphatemia, high phosphate intake, and vitamin D deficiency. (See <a href=\"#H2773888503\" class=\"local\">'Treat persistent and progressive hyperparathyroidism'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We generally treat patients who have a serum phosphate that is persistently above normal and progressively worsening. (See <a href=\"#H1051197753\" class=\"local\">'Treat hyperphosphatemia'</a> above and <a href=\"topic.htm?path=management-of-hyperphosphatemia-in-chronic-kidney-disease#H89993305\" class=\"medical medical_review\">&quot;Management of hyperphosphatemia in chronic kidney disease&quot;, section on 'Nondialysis chronic kidney disease patients'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We do not specifically treat mild and asymptomatic hypocalcemia, because of the associated risk of hypercalcemia, although hypocalcemia may be addressed in part by correction of vitamin D deficiency and treatment of hyperphosphatemia. (See <a href=\"#H3299247461\" class=\"local\">'Hypocalcemia'</a> above and <a href=\"topic.htm?path=clinical-manifestations-of-hypercalcemia\" class=\"medical medical_review\">&quot;Clinical manifestations of hypercalcemia&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-of-hypocalcemia\" class=\"medical medical_review\">&quot;Clinical manifestations of hypocalcemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We treat vitamin D deficiency according to guidelines for the general population. (See <a href=\"topic.htm?path=vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment\" class=\"medical medical_review\">&quot;Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients who have PTH values that are persistently greater than 150 to 200 <span class=\"nowrap\">pg/mL</span> (or approximately 2.3 to 3.0 times an upper limit of normal of 65 <span class=\"nowrap\">pg/mL)</span> despite treatment of hyperphosphatemia, high phosphate intake, and vitamin D deficiency, we suggest <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> or an active vitamin D analog (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Calcitriol and synthetic vitamin D analogs reduce or stabilize PTH and improve bone histology, though have not been shown to provide benefits in clinically important outcomes. A preferred agent and starting dose is calcitriol at 0.25 mcg three times weekly. We adjust the dose to maintain PTH &lt;150 <span class=\"nowrap\">pg/mL</span>. We do not use calcitriol if the serum phosphate is above normal range or if the corrected serum total calcium concentration is &ge;9.5 <span class=\"nowrap\">mg/dL</span> (&ge;2.37 <span class=\"nowrap\">mmol/L)</span>. (See <a href=\"#H2773888503\" class=\"local\">'Treat persistent and progressive hyperparathyroidism'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H101040271\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate would like to acknowledge Robert E Cronin, MD, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/1\" class=\"nounderline abstract_t\">Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6:913.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/2\" class=\"nounderline abstract_t\">Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney&nbsp;Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017; 92:26.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/3\" class=\"nounderline abstract_t\">Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26:1948.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/4\" class=\"nounderline abstract_t\">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/5\" class=\"nounderline abstract_t\">Kramer H, Berns JS, Choi MJ, et al. 25-Hydroxyvitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report. Am J Kidney Dis 2014; 64:499.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/6\" class=\"nounderline abstract_t\">Al-Aly Z, Qazi RA, Gonz&aacute;lez EA, et al. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50:59.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/7\" class=\"nounderline abstract_t\">Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27:36.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/8\" class=\"nounderline abstract_t\">Kooienga L, Fried L, Scragg R, et al. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 2009; 53:408.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/9\" class=\"nounderline abstract_t\">Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6:50.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/10\" class=\"nounderline abstract_t\">Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310:358.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/11\" class=\"nounderline abstract_t\">Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19:870.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/12\" class=\"nounderline abstract_t\">Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47:263.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/13\" class=\"nounderline abstract_t\">Ting SM, Iqbal H, Kanji H, et al. Functional cardiovascular reserve predicts survival pre-kidney and post-kidney transplantation. J Am Soc Nephrol 2014; 25:187.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/14\" class=\"nounderline abstract_t\">Kovesdy CP, Lu JL, Malakauskas SM, et al. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 2012; 59:58.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/15\" class=\"nounderline abstract_t\">Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. J Am Soc Nephrol 2014; 25:175.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/16\" class=\"nounderline abstract_t\">Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307:674.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/17\" class=\"nounderline abstract_t\">Slatopolsky E, Berkoben M, Kelber J, et al. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl 1992; 38:S43.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/18\" class=\"nounderline abstract_t\">Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005; 46:58.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/19\" class=\"nounderline abstract_t\">Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 2009; 53:197.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-nondialysis-patients-with-chronic-kidney-disease/abstract/20\" class=\"nounderline abstract_t\">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1964 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1301799786\" id=\"outline-link-H1301799786\">RATIONALE</a></li><li><a href=\"#H2395990131\" id=\"outline-link-H2395990131\">ASSESSMENT AND MONITORING</a><ul><li><a href=\"#H4215055417\" id=\"outline-link-H4215055417\">eGFR 30 to 59 mL/min/1.73 m2</a></li><li><a href=\"#H632673499\" id=\"outline-link-H632673499\">eGFR 15 to 29 mL/min/1.73 m2</a></li><li><a href=\"#H533307997\" id=\"outline-link-H533307997\">eGFR &lt;15 mL/min/1.73 m2</a></li></ul></li><li><a href=\"#H1752618100\" id=\"outline-link-H1752618100\">INITIAL TREATMENT</a><ul><li><a href=\"#H1051197753\" id=\"outline-link-H1051197753\">Treat hyperphosphatemia</a></li><li><a href=\"#H3299247461\" id=\"outline-link-H3299247461\">Hypocalcemia</a></li><li><a href=\"#H2953807510\" id=\"outline-link-H2953807510\">Treat vitamin D deficiency</a></li><li><a href=\"#H2773888503\" id=\"outline-link-H2773888503\">Treat persistent and progressive hyperparathyroidism</a></li></ul></li><li><a href=\"#H24\" id=\"outline-link-H24\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H101040271\" id=\"outline-link-H101040271\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bone-biopsy-and-the-diagnosis-of-renal-osteodystrophy\" class=\"medical medical_review\">Bone biopsy and the diagnosis of renal osteodystrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-hypercalcemia\" class=\"medical medical_review\">Clinical manifestations of hypercalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-hypocalcemia\" class=\"medical medical_review\">Clinical manifestations of hypocalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-hyperphosphatemia-in-chronic-kidney-disease\" class=\"medical medical_review\">Management of hyperphosphatemia in chronic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-secondary-hyperparathyroidism-in-dialysis-patients\" class=\"medical medical_review\">Management of secondary hyperparathyroidism in dialysis patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd\" class=\"medical medical_review\">Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=refractory-hyperparathyroidism-and-indications-for-parathyroidectomy-in-dialysis-patients\" class=\"medical medical_review\">Refractory hyperparathyroidism and indications for parathyroidectomy in dialysis patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment\" class=\"medical medical_review\">Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment</a></li></ul></div></div>","javascript":null}